IIM
LENZ

INTECH Investment Management’s LENZ Therapeutics LENZ Stock Holding History

INTECH Investment Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,343
Closed -$295K – 2470
2025
Q3 		$295K Sell
6,343
-2,908
-31% -$107K ﹤0.01% 1829
2025
Q2 		$271K Buy
9,251
+380
+4% +$10.3K ﹤0.01% 1925
2025
Q1 		$228K Buy
8,871
+1,425
+19% +$35.1K ﹤0.01% 2024
2024
Q4 		$215K Buy
+7,446
New +$227K ﹤0.01% 1998

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

INTECH Investment Management's LENZ Position: Q4 2025 in Review

INTECH Investment Management sold out of LENZ Therapeutics (LENZ) in Q4 2025, closing a stake of 6,343 shares — an estimated $295K sold.

INTECH Investment Management first reported a position in LENZ in Q4 2024 and held it in 4 quarters. The position peaked at $295K in Q3 2025. 160 funds tracked by Wall St. Rank hold LENZ as of Q4 2025.

  • INTECH Investment Management reported no remaining LENZ Therapeutics position as of Q4 2025 after selling out during the quarter.
  • INTECH Investment Management sold 6,343 LENZ Therapeutics shares in Q4 2025, an estimated $295K.
  • INTECH Investment Management first reported a position in LENZ Therapeutics in Q4 2024 and held it in 4 quarters.
  • INTECH Investment Management's LENZ Therapeutics position peaked at $295K in Q3 2025.
  • 160 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2025.

Based on INTECH Investment Management's 13F filing for Q4 2025, filed 10 Feb 2026.